Repeat: Treatment.com AI announces AI Pharmacy Assistant
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has announced a new AI Pharmacy Assistant solution, set to launch in 2024. This tool aims to support pharmacists in their expanding role in healthcare, particularly in providing clinical decision support services. The AI Pharmacy Assistant is powered by Treatment's proprietary Global Library of Medicine (GLM), offering features such as:
- Automated patient history and symptom recording
- Documentation of patient interactions
- Enhanced diagnostic support
- Error minimization and increased clinical efficiency
- Comprehensive diagnostic information backed by up-to-date medical research
The global clinical decision support systems market is projected to grow from $2.46 billion in 2024 to $4.05 billion by 2029. This new product line represents an additional revenue stream for Treatment.com AI's GLM platform.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) ha annunciato una nuova soluzione di assistente farmaceutico basata su AI, in programma per il lancio nel 2024. Questo strumento mira a supportare i farmacisti nel loro ruolo in espansione nella sanità, in particolare nella fornitura di servizi di supporto alle decisioni cliniche. L'assistente farmaceutico AI è alimentato dalla Biblioteca Globale della Medicina (GLM) proprietaria di Treatment, offrendo funzioni come:
- Registrazione automatica della storia clinica e dei sintomi dei pazienti
- Documentazione delle interazioni con i pazienti
- Supporto diagnostico avanzato
- Minimizzazione degli errori e aumento dell'efficienza clinica
- Informazioni diagnostiche complete supportate da ricerche mediche aggiornate
Il mercato globale dei sistemi di supporto alle decisioni cliniche è previsto crescere da 2,46 miliardi di dollari nel 2024 a 4,05 miliardi di dollari entro il 2029. Questa nuova linea di prodotti rappresenta una fonte di reddito aggiuntiva per la piattaforma GLM di Treatment.com AI.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) ha anunciado una nueva solución de Asistente Farmacéutico de AI, que se lanzará en 2024. Esta herramienta tiene como objetivo apoyar a los farmacéuticos en su papel en expansión en la atención médica, especialmente en la prestación de servicios de apoyo a la decisión clínica. El Asistente Farmacéutico AI es impulsado por la Biblioteca Global de Medicina (GLM) propietaria de Treatment, ofreciendo características como:
- Registro automatizado de la historia clínica y síntomas del paciente
- Documentación de las interacciones con los pacientes
- Soporte diagnóstico mejorado
- Minimización de errores y aumento de la eficiencia clínica
- Información diagnóstica completa respaldada por investigaciones médicas actualizadas
Se proyecta que el mercado global de sistemas de apoyo a la decisión clínica crecerá de 2.46 mil millones de dólares en 2024 a 4.05 mil millones de dólares para 2029. Esta nueva línea de productos representa una fuente de ingresos adicional para la plataforma GLM de Treatment.com AI.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF)는 2024년에 출시될 새로운 AI 약국 보조 솔루션을 발표했습니다. 이 도구는 건강 관리에서의 역할이 확장된 약사들을 지원하는 것을 목표로 하며, 특히 임상 결정 지원 서비스를 제공하는 데 중점을 두고 있습니다. AI 약국 보조기는 Treatment의 독점 글로벌 의학 라이브러리(GLM)를 통해 구동되며, 다음과 같은 기능을 제공합니다:
- 자동화된 환자 이력 및 증상 기록
- 환자 상호작용 문서화
- 향상된 진단 지원
- 오류 최소화 및 임상 효율성 증가
- 최신 의료 연구에 기반한 종합 진단 정보
글로벌 임상 결정 지원 시스템 시장은 2024년 24억 6천만 달러에서 2029년 40억 5천만 달러로 성장할 것으로 예상됩니다. 이 새로운 제품 라인은 Treatment.com AI의 GLM 플랫폼에 대한 추가 수익원으로 자리잡고 있습니다.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) a annoncé une nouvelle solution d'assistant pharmaceutique AI, prévue pour un lancement en 2024. Cet outil vise à soutenir les pharmaciens dans leur rôle croissant en matière de santé, en particulier dans la fourniture de services de soutien à la décision clinique. L'assistant pharmaceutique AI est alimenté par la Bibliothèque Globale de Médecine (GLM) propriété de Treatment, et offre des fonctionnalités telles que :
- Enregistrement automatisé de l'historique des patients et des symptômes
- Documentation des interactions avec les patients
- Soutien diagnostique amélioré
- Minimisation des erreurs et augmentation de l'efficacité clinique
- Informations diagnostiques complètes soutenues par des recherches médicales à jour
Le marché mondial des systèmes de soutien à la décision clinique devrait passer de 2,46 milliards de dollars en 2024 à 4,05 milliards de dollars d'ici 2029. Cette nouvelle gamme de produits représente une source de revenus supplémentaire pour la plateforme GLM de Treatment.com AI.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) hat eine neue AI-Apothekenassistenten-Lösung angekündigt, die 2024 auf den Markt kommen soll. Dieses Werkzeug zielt darauf ab, Apotheker in ihrer erweiterten Rolle im Gesundheitswesen zu unterstützen, insbesondere bei der Bereitstellung von klinischen Entscheidungsunterstützungsdiensten. Der AI-Apothekenassistent basiert auf der proprietären Global Library of Medicine (GLM) von Treatment und bietet Funktionen wie:
- Automatisierte Erfassung von Patientenhistorie und Symptomen
- Dokumentation der Patienteninteraktionen
- Verbesserte diagnostische Unterstützung
- Fehlerreduzierung und erhöhte klinische Effizienz
- Umfassende diagnostische Informationen, unterstützt durch aktuelle medizinische Forschung
Der globale Markt für Systeme zur klinischen Entscheidungsunterstützung wird voraussichtlich von 2,46 Milliarden Dollar im Jahr 2024 auf 4,05 Milliarden Dollar bis 2029 wachsen. Diese neue Produktlinie stellt eine zusätzliche Einnahmequelle für die GLM-Plattform von Treatment.com AI dar.
- Launch of new AI Pharmacy Assistant solution in 2024, expanding product offerings
- Potential to tap into growing clinical decision support systems market, projected to reach $4.05 billion by 2029
- AI solution aims to improve efficiency and reduce errors in pharmacy operations
- Addresses global pharmacist shortage by providing supportive and accurate tools
- None.
VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is excited to announce a new solution, AI Pharmacy Assistant designed to support pharmacists. Pharmacists are playing an increasing role in the provision of clinical decision support services, given the increasing number of people without a GP and/or the time taken to book appointments.
As one example, the Ontario government recently announced pharmacies provided over 1 million assessments for common ailments since last year Ontario Exploring More Ways to Expand Role of Pharmacists | Ontario Newsroom. This is representative of similar trends being seen across Canada, UK and emerging legislation in the US, all of which will lead to extending the role for pharmacists within the healthcare continuum of care. Globally, pharmacists will play a significant role in alleviating the shortages of healthcare professionals, timeliness of patient support and mitigating the financial pressures prevalent in today’s healthcare systems.
For many people, especially in underserved communities, the pharmacist is often the only healthcare professional people see. Therefore, providing these pharmacists with the tools and confidence to administer a wider range of services, has a positive impact for them and the wellbeing of their communities.
Working with pharmacists, Treatment is excited to be announcing its new AI Pharmacy Assistant solution for pharmacists, expected to launch later in 2024. The solution is underpinned by Treatment’s AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library. The GLM has been created with hundreds of credentialled clinicians globally to ensure the highest qualified clinical information and support to all healthcare professionals.
AI Pharmacy Assistant will be either accessible on a patient's mobile device or through a kiosk tablet at the pharmacy. It will support pharmacists in multiple ways:
- Reducing the time to take patient histories and symptoms using Treatment’s GLM
- Automatically document all interactions with patients providing an audit trail
- Extending confidence and support in expanded diagnostic support provided to patients
- Minimize the risk of errors and increase clinical efficiency
- Providing comprehensive diagnostic and symptom information backed by the most reliable and up-to-date medical research
The global clinical decision support systems (CDSS) market is projected to grow significantly, reaching approximately
Dr. Essam Hamza, CEO of Treatment.com AI, comments: “We are excited to announce another new product line and revenue stream for our GLM platform. We have been working closely with industry professionals and government agencies to ensure we create a valuable tool that will have the most immediate impact for all the stakeholders. For Payers, we help improve efficiency and hopefully avoid patient complications and unneeded costly hospital visits. For the Pharmacists, we help relieve administrative headaches and give them comfort to see more patients. Finally, and most importantly, for the Patient, we provide more and better access to care for themselves and their family members.”
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
If you would like to find out more about Treatment’s products and services, please email at info@treatment.com
For media inquiries, contact: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statements
This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
FAQ
What is Treatment.com AI's new product announcement for 2024?
How does the AI Pharmacy Assistant aim to help pharmacists?
What is the projected market size for clinical decision support systems by 2029?